Volume 112, Issue 6 e24168
REVIEW

How to overcome endosomal entrapment of cell-penetrating peptides to release the therapeutic potential of peptides?

Ferran Nadal-Bufí

Corresponding Author

Ferran Nadal-Bufí

School of Biomedical Sciences, Faculty of Health, Institute of Health & Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia

Correspondence

Ferran Nadal-Bufí, School of Biomedical Sciences, Faculty of Health, Institute of Health & Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, QLD 4102, Australia.

Email: [email protected]

Search for more papers by this author
Sónia Troeira Henriques

Sónia Troeira Henriques

School of Biomedical Sciences, Faculty of Health, Institute of Health & Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia

Search for more papers by this author
First published: 07 May 2020
Citations: 13

Funding information: Australian Research Council, Grant/Award Number: FT150100398; Queensland University of Technology, Grant/Award Number: Postgraduate Research Award

Abstract

Peptides gained a renascent interest as alternative pharmaceuticals, and in particular as anticancer drugs to inhibit intracellular proteins involved in cancer pathways, inaccessible to other pharmaceutical agents. However, the use of peptides as therapeutics is still limited by difficulties in reaching the protein target located in the cytosol. Cell penetrating peptides (CPPs) are being explored as tools to deliver therapeutic peptides inside cells, but they often enter cells using endocytic pathways and become entrapped inside endosomes. Therefore, a strategy to unleash the potential of peptides as therapeutics is to control the release of CPPs from endosomes. In this review we summarize recent strategies employed to improve endosomal escape of CPPs. Lessons learned from these studies can guide the design of CPPs as tools to deliver peptide sequences able to inhibit cancer targets and accelerate their development as therapeutics.

Graphical Abstract

CONFLICT OF INTEREST

The authors declare no competing interests.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.